Based on data from [1], we developed an externally validated mechanistic population model of the origination and development of an anti-tumor T cell immune response linked to CT26 tumor size dynamics, following treatment with anti-PD-L1 mAb therapy alone and in combination with RT in a mouse model (Fig 1A). The gene discussed is DDX53; the disease is neoplasm.